Caribou Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Caribou Biosciences, Inc. announced that its CEO will be presenting at investor conferences in May.

Positive

• The CEO's presentation at investor conferences may generate interest and positive sentiment among investors.

Negative

• No negative takes were found.

BERKELEY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, is scheduled to present at the following investor conferences during the month of May:

• BofA Securities 2023 Healthcare Conference, Las Vegas, NV
  May 10, 2023, 3:00 pm PDT
  Webcast
• RBC Capital Markets Global Healthcare Conference, New York
  May 16, 2023, 2:35 pm EDT
  Webcast to be made available on Events page

For more information, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for 30 days after the event.

About Caribou’s Novel Next-Generation CRISPR Platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems have exhibited editing at unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve antitumor activity. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T and CAR-NK platforms as readily available treatments for patients with hematologic malignancies and solid tumors. Follow us @CaribouBio and visit www.cariboubio.com.

Caribou Biosciences, Inc. Contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com

Media:
Peggy Vorwald, PhD
media@cariboubio.com

FAQ

When and where will Rachel Haurwitz be presenting?

Rachel Haurwitz, CEO of Caribou Biosciences, will be presenting at the BofA Securities 2023 Healthcare Conference in Las Vegas on May 10, 2023, and at the RBC Capital Markets Global Healthcare Conference in New York on May 16, 2023.

Will the presentations be available for viewing online?

Yes, webcasts of the presentations will be made available on the Caribou website for 30 days after the events.

What is the significance of these presentations?

The presentations provide an opportunity for Caribou Biosciences to showcase its progress and future plans to potential investors, which could positively impact the company's stock price.